Stockscreener 앱 받기
33.92
1.10%
0.37
시간 외 거래:
33.93
0.010
+0.03%
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics: Phase 3 Obesity Data Feels Like A Coin Toss (Rating Downgrade) (VKTX) - Seeking Alpha
VIKING THERAPEUTICS, INC. (VKTX) - MSN
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider - MSN
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum? - TradingView
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market - MSN
Better weight loss drug stock buy: Eli Lilly vs Viking Therapeutics - MSN
Weight Loss Drug Market Analysis 2026: Leaders, Oral Drugs & Competitive LandscapeNews and Statistics - IndexBox
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - Yahoo Finance
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics - The Motley Fool
Viking Therapeutics, Inc. $VKTX Shares Sold by Kintayl Capital LP - MarketBeat
Viking Therapeutics, Inc. (VKTX) Outperforms the Market: Key Points to Note - Bitget
Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) suffers a larger drop than the general market: Key insights - MSN
Jim Cramer Recommends Eli Lilly Over Viking Therapeutics - MSN
3 Companies at the Forefront of the GLP-1 Pill Wars - MarketBeat
Why is Viking Therapeutics (VKTX) up 16.3% since last earnings report? - MSN
Granahan Investment Management LLC Sells 115,562 Shares of Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. $VKTX Stock Holdings Cut by Braidwell LP - MarketBeat
Baker BROS. Advisors LP Acquires New Shares in Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics (VKTX) Valuation Check As Obesity Drug VK2735 Advances Into Phase 3 Trials - simplywall.st
Viking Therapeutics, Inc. $VKTX Shares Acquired by Quinn Opportunity Partners LLC - MarketBeat
Is Viking Therapeutics (VKTX) one of the shorted biotech stocks to invest in? - MSN
Viking Therapeutics rises after Q4 updates on obesity therapy - MSN
Why Viking Therapeutics (VKTX) Is Up 12.6% After Fast-Tracking VK2735 Into Late-Stage Obesity TrialsAnd What's Next - simplywall.st
Why Has Viking Therapeutics (VKTX) Increased by 16.3% Since Its Previous Earnings Announcement? - Bitget
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report? - Yahoo Finance
VKTX Stock Extends Red-Hot Streak: Insider Scoops Up Shares As Multiple Phase 3 Trials Loom This Year In Obesity Race - Stocktwits
Viking Therapeutics Phase 3 Obesity Move Tests VK2735 Valuation Gap - Sahm
Is Viking Therapeutics (VKTX) Price Move Justified By DCF And Book Value Signals - Yahoo Finance
Jefferies Maintains Buy on Viking Therapeutics, Inc. (VKTX) March 2026 - Meyka
Jefferies reiterates Buy on Viking Therapeutic stock, $101 target - Investing.com
Can Viking Therapeutics Capitalize on Weight Loss Drugs for a Comeback? - NAI500
Net current asset value per share of Viking Therapeutics, Inc. – LS:A12GD6 - TradingView
WINTON GROUP Ltd Buys Shares of 68,700 Viking Therapeutics, Inc. $VKTX - MarketBeat
Here's Why Viking Therapeutics Stock Recovered and Can Soar in 2026 - The Motley Fool
Here's Why Viking Therapeutics Stock Recovered and Can Soar 2026 - AOL.com
1.20%
0.06%
자본화:
|
볼륨(24시간):